Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BM 201 - InnoBM Pharmaceuticals

Next Previous
Drug Profile

BM 201 - InnoBM Pharmaceuticals

Alternative Names: BM-201 - InnoBM Pharmaceuticals

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoBM Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Solid tumours

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (Intratumoural, Controlled release)
  • 02 Jun 2026 Pooled efficacy, adverse events and pharmacokinetics data from the phase 0 and phase I trial in Solid tumours were presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 19 Apr 2024 InnoBM Pharmaceuticals has a pending patent application for 'self-sustained release immune adjuvant suspension, preparation method therefor, and use thereof'

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top